Slingshot members are tracking this event:

OncoSec (ONCS) Announces Interim Data from KEYNOTE-695 Trial in Anti-PD-1 Checkpoint Refractory Metastatic Melanoma at SITC 2020

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Clinical Data Key highlights of KEYNOTE-695 include:
  • Of the first 54 out of 100 planned patients evaluated by investigator-assessed RECIST v1.1:
    • ORR was 30% (95%CI [18.0%, 43.6%]) (16/54)
    • Complete response rate was 6% (3/54)
    • All responses were confirmed by scans taken no earlier than after 6 months on study
    • 9% (5/54) patients had 100% reduction of target lesions
    • ORR was 35% (n=6/17) in patients with Stage IV M1c/M1d disease
    • ORR was 40% (n=6/15) in patients with prior exposure to ipilimumab
    • Median duration of response (mDOR) is currently 12.2 months (95% CI, 5.6-NE)
    • Median study follow-up was 13.5 months
  • Excellent safety profile resulting from intramural treatment approach
    • Only 5.4% Grade 3 treatment-related AEs
    • No grade 4/5 treatment-related AEs
  • This study enrolled rapidly progressing patients with a short interval of 1.2 months (median) between the last dose of anti-PD-1 and study treatment
Slingshot Insights Explained
Catalyst Date
Occurred on:
Nov 09, 2020
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Keynote-695, Pd-1, Metastatic Melanoma, Sitc 2020